The AMR Centre is part of the CARB-X consortium.

CARB-X is a new, global public-private partnership, funded in part by the United States government, in partnership with major institutions in the United Kingdom. The goal is to dramatically restart global antibiotic R&D by providing hundreds of millions of dollars in pre-clinical R&D support over the next 5 years.

The goal for CARB-X is to have many more opportunities for innovative molecules that target resistant bacteria to find their way out of the university research lab, and into clinical testing.

The AMR Centre has come out of discussions over the past 18 months between a number of parties in the public and private sector based in the North of England. If untreated, AMR could kill 10 million patients worldwide by 2050 – causing more deaths than cancer.